Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes: Gradient of benefit related to the revascularization strategy

M. Roffi, D. P. Chew, D. Mukherjee, D. L. Bhatt, J. A. White, D. J. Moliterno, C. Heeschen, C. W. Hamm, M. A. Robbins, N. S. Kleiman, P. Théroux, H. D. White, E. J. Topol

Research output: Contribution to journalArticle

141 Citations (Scopus)


Aims: To assess the efficacy of platelet glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes primarily medically managed. Methods and Results: We performed a meta-analysis of the randomized clinical trials of platelet glycoprotein IIb/IIIa inhibitor therapy in the medical management of non-ST-elevation acute coronary syndromes. Among 29 570 patients, IIb/IIIa integrin blockade was associated with a reduction in death or non-fatal myocardial infarction at 30 days, from 11·5% to 10·7% (odds ratio 0·91, P=0·02). Patients undergoing percutaneous coronary intervention during index hospitalization sustained a greater reduction in ischaemic events (odds ratio 0·82, P=0·01) than patients medically managed (odds ratio 0·95, P=0·27). Among patients undergoing intervention, the benefit was more pronounced if the procedure was performed during glycoprotein IIb/IIIa inhibitor infusion (odds ratio 0·74; P=0·02), than if revascularization was performed after drug discontinuation (odds ratio 0·87, P=0-17). Conclusion: This analysis, including the entire large-scale trial experience of intravenous glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes primarily medically managed, demonstrates an overall significant, albeit moderate, reduction in 30-day death or myocardial infarction associated with therapy. Although not based on a prospectively defined hypothesis, the findings suggest a gradient of benefit conferred by these agents depending on the revascularization strategy used.

Original languageEnglish
Pages (from-to)1441-1448
Number of pages8
JournalEuropean heart journal
Issue number18
Publication statusPublished - 1 Sep 2002


  • Abciximab
  • Acute coronary syndromes
  • Eptifibatide
  • Glycoprotein IIb/IIIa receptor inhibitors
  • Lamifiban
  • Tirofiban

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this